RE:Big Pharma lining up OV therapy to follow ONCY's pelareorepTILT-123's viral construct tries to replicate the same mechansim of action that ONCY has already demonstrated with pelareorep which deals with activating T cells from the patient’s immune system and then trafficing these "activated T-cells" to the tumor microenvironment, turning ‘cold’ tumors ‘hot’.
TILT Biotherapeutics' work towards turning cold tumors hot again demonstrates that Big Pharma is interested in what ONCY's pelareorep's has accomplished, while also demonstrating that pelareorep is well ahead of the curve in the field of combination I/O therapy in the treatment of various cancers using immuno-oncology therapeutics.
Furthermore, ONCY has a predictive biomarker diagnostic to identify which patients will best respond to the combination of pelareorep + immune checkpoint inhibitors. TILT Biotherapeutics does not !